A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity.

ABSTRACT:

Background

The treatment and prognosis of de novo metastatic hormone-sensitive prostate cancer (mHSPC) vary. We established and validated a novel prognostic model for predicting cancer-specific survival (CSS) in patients with mHSPC using retrospective data from a contemporary cohort.

Methods

1092 Japanese patients diagnosed with de novo mHSPC between 2014 and 2020 were registered. The patients treated with androgen deprivation therapy and first-generation anti-androgens (ADT/CAB) were assigned to the Discovery (N = 467) or Validation (N = 328) cohorts. Those treated with ADT and androgen-receptor signaling inhibitors (ARSIs) were assigned to the ARSI cohort (N = 81).

Results

Using the Discovery cohort, independent prognostic factors of CSS, the extent of disease score

SUBMITTER: Fujiwara H 

PROVIDER: S-EPMC11420339 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature